Capricor Therapeutics announces promising long-term results for deramiocel deramiocel in Duchenne muscular dystrophy

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company at the forefront of developing cell and exosome-based therapies, has shared encouraging three-year safety and efficacy results from ... Read More